期刊
LEUKEMIA & LYMPHOMA
卷 58, 期 5, 页码 1022-1036出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2016.1228927
关键词
AML; MDS; hypomethylating agent; DNA methyltransferase; inhibitor; epigenetic; combination therapy
资金
- Celgene
The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a significant advancement, HMA lead to responses in less than half of patients and for those that respond most will relapse. As such, there is a crucial need to improve frontline therapy approaches. One promising strategy involves combining azacitidine or decitabine with investigational or existing therapies with the goal of achieving synergistic activity and better patient outcomes. The purpose of this paper is to critically review the efficacy and safety of reported HMA-based combination regimens in patients with higher-risk MDS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据